D. E. Shaw & Co., Inc. Acadia Pharmaceuticals Inc Transaction History
D. E. Shaw & Co., Inc.
- $114 Billion
- Q1 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 2,642,020 shares of ACAD stock, worth $41.2 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
2,642,020
Previous 3,754,598
29.63%
Holding current value
$41.2 Million
Previous $118 Million
58.45%
% of portfolio
0.04%
Previous 0.11%
Shares
25 transactions
Others Institutions Holding ACAD
# of Institutions
299Shares Held
158MCall Options Held
1.88MPut Options Held
688K-
Baker Bros. Advisors LP New York, NY42.9MShares$669 Million10.04% of portfolio
-
Rtw Investments, LP New York, NY13.8MShares$216 Million4.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$207 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$182 Million0.01% of portfolio
-
State Street Corp Boston, MA6MShares$93.6 Million0.01% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $2.52B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...